Ocular toxicology

Current Opinion in Ophthalmology

Volumn 8, Issue 6, 1997, Pages 88-92

  Novack, Gary D ^a  

^a PHARMALOGIC DEVELOPMENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; COCAINE; COLLAGEN; CORTICOSTEROID; CYCLOPENTOLATE; DEFEROXAMINE; GLUCOSE; HYDROXYCHLOROQUINE; KETOROLAC; METHOTREXATE; PENTOXIFYLLINE; PILOCARPINE; RIFABUTIN; XENOBIOTIC AGENT;

AQUEOUS HUMOR; ASTHMA; COLOR VISION; DIABETES MELLITUS; EYE BLOOD FLOW; EYE TOXICITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAOCULAR HYPERTENSION; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINOPATHY; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION; URTICARIA; UVEITIS; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EYE; EYE DISEASES; HUMANS; SAFETY; XENOBIOTICS;

EID: 0031469457     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199712000-00016     Document Type: Short Survey

References (26)

1. Novack GD: Ocular toxicology. Curr Opin Ophthalmol 1993, 4:125-128.
2. Novack GD: Ocular toxicology. Curr Opin Ophthalmol 1994, 5:110-114.
3. Novack GD: Ocular toxicology. Curr Opin Ophthalmol 1995, 6:108-112.
4. Bayer AU, Thiel HJ, Zrenner E, Dichgans J, Kuehn M, Paulus W, Ried S, Schmidt D: Color vision tests for early detection of antiepileptic drug toxicity. Neurology 1997, 48:1394-1397.
5. Eke T, Talbot JF, Lawden MC: Severe persistent visual field constriction associated with vigabatrin. BMJ 1997, 314:180-181.
6. Garbe E, Lelorier J, Boivin J-F, Sulssa S: Inhaled and nasal glucocorti coids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997, 277:722-727. Good use of the Quebec provincial health insurance program data. The findings, although consistent with scientific knowledge about corticosteroids and intraocular pressure, show a relatively low odds ratio (1.44, 95% confidence interval, 1.01-2.06) and thus, probably do not warrant the strong recommendations of this report.
7. Becker B, Mills DW: Corticosteroids and intraocular pressure. Arch Ophthalmol 1963, 70:500-507.
8. Bernstein HN, Mills DW, Becker B: Steroid-induced elevation of intraocular pressure. Arch Ophthalmol 1963, 70:59-62.
9. Podos SM, Kruptin T, Asseff C, Becker B: Topically administered corticosteroid preparations. Arch Ophthalmol 1971, 86:251-254.
10. Kmietowicz Z: Inhaled steroids increase risk of glaucoma. BMJ 1997, 314:697.
11. Desatnik HR, Gutman FA: Bilateral exudative retinal detachment complicating systemic corticosteroid therapy in the presence of renal failure. Am J Ophthalmol 1996, 122:432-434.
12. Chaknis MJ, Brooks SE, Mitchell KT, Marcus DM: Inflammatory opacities of the vitreous in rifabutin-associated uveitis. Am J Ophthalmol 1996, 122:580-582.
13. Gioulekas J, Hall A: Uveitis associated with rifabutin therapy. Aust NZ J Ophthalmol 1995, 23:319-321.
14. Contestabile MT, Suppressa F, Tonelli G, Giorgi G, D'Alba E, Bruno P: Evaluation of hydroxychloroquinone retinal toxicity. Ann Ophthalmol 1996, 28:376-383.
15. Schmetterer L, Kemmler D, Breiteneder H, Alschinger C, Koppensteiner R, Lexer F, Fercher AF, Eichler HG, Wolzt M: A randomized, placebo-controlled, double-blind crossover study of the effect of pentoxifylline on ocular fundus pulsations. Am J Ophthalmol 1996, 121:169-176. This study shows a clear-cut result of a single infusion of pentoxifylline on ocular fundus pulsations. However, the clinical impact of these findings is subject to great discussion.
16. MacKay CJ: A randomized, placebo-controlled, double-blind crossover study of the effect of pentoxifylline on ocular fundus pulsations [letter; comment]. Am J Ophthalmol 1996, 122:282-283.
17. Silva-Araujo A, Tavares MA, Patacao MH, Carolino RM: Retinal hemor rhages associated with in utero exposure to cocaine: experimental and clinical findings. Retina 1996, 16:411-418. This is an excellent example of use of both clinical observations and prospective animal studies to evaluate a hypothesis.
18. Mullins RJ, Richards C, Walker T: Allergic reactions to oral, surgical and topical bovine collagen: anaphylactic risk for surgeons. Aust NZ J Ophthalmol 1996, 24:257-260.
19. North RV, Cooney O, Chambers D, Dolben J, Owens DR: Does hypergly caemia have an influence upon colour vision of patients with diabetes mellitus? Ophthalmic Physiol Opt 1997, 17:95-101. An excellent study of a common clinical finding: variation in color vision with fluctuating glucose levels.
20. Spraul CW, Schicketanz C, Lang GE: Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis. Klin Monatsbl Augenheilkd 1996, 209:31-36.
21. de Smet MD, Stark-Vancs V, Kohler DR, Smith J, Wittes R, Nussenblatt RB: Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996, 121:442-444.
22. Kushnick H, Liebmann JM, Ritch R: Systemic pilocarpine toxicity from Ocusert leakage [letter]. Arch Ophthalmol 1996, 114:1432.
23. Newman DK, Jordan K: Generalised urticaria induced by topical cyclopentolate [letter]. Eye 1996, 10:750-751.
24. Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA: Asthma caused by topical application of ketorolac. Ophthalmology 1996, 103:890-892.
25. Mack CJ: A retrospective study of the incidence of adverse drug reactions from topical ocular medications. Clin Eye Vis Care 1996, 8:265-268.
26. Dangelmaier S, Weindler J, Ruprecht KW: Drug side-effects of the eye: a contribution to quality assurance in ophthalmology. Klin Monatsbl Augenheilkd 1996, 208:385-388.